Data Article

Cell cycle progression data on human skin cancer cells with anticancer synthetic peptide LTX-315 treatment

Gloria A. Santa-González\textsuperscript{a,b}, Edwin Patiño-González\textsuperscript{a,b}, Marcela Manrique-Moreno\textsuperscript{b,*}

\textsuperscript{a} Genetic Regeneration and Cancer Group, Faculty of Exact and Natural Sciences, Biology Institute, University of Antioquia, A.A. 1226, Medellin, Colombia
\textsuperscript{b} Structural Biochemistry of Macromolecules Group, Faculty of Exact and Natural Sciences, Chemistry Institute, University of Antioquia, A.A. 1226, Medellin, Colombia

\textbf{A B S T R A C T}

Skin cancer, including melanoma and non-melanoma (NMSC), represents the most common type of malignancy in the white population [1]. The incidence rate of melanoma is increasing worldwide, while the associated mortality remains stable. On the other hand, the incidence of NMSC varies widely [1,2]. Camilio and collaborators recently described the anticancer properties of LTX-315, a novel synthetic anticancer peptide, commercialized as Oncopore\textsuperscript{TM} [3,4]. Despite various studies demonstrating the efficiency of LTX-315 therapy in inducing cancer cell death, the effects on cell cycle progression of this antitumoral peptide are poorly understood. In this research, we present data about the effect of LTX-315 on the cell cycle of two skin cancer cell lines: epidermoid carcinoma cells (A431) and melanoma cells (A375); as well as on an immortalized normal keratinocyte cell line, HaCaT. Additionally, its cytotoxicity on the cells was determined by measuring the uptake of propidium iodide, in order to establish its relationship with cell cycle progression. The analysed data obtained by flow cytometry show different cell cycle distributions in non-tumoral and skin cancer-derived cell lines in response to LTX-315 treatment. Non-tumoral cells showed a sub-G1 peak, while

\textsuperscript{*} Corresponding author at: Calle 67 # 53 – 108, Bloque 2-235, Medellin, Colombia.
E-mail address: marcela.manrique@udea.edu.co (M. Manrique-Moreno).

\url{https://doi.org/10.1016/j.dib.2020.105443}

\textsuperscript{2352-3409/© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license.}
\url{(http://creativecommons.org/licenses/by/4.0/)}
for tumoral cells there was a shift in the G1 peak without producing an obvious distant and distinct sub-G1 peak. This data is in accordance with a major decrease in cell viability in non-cancer cells.

© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)

### Specifications table

| Subject | Biochemistry, Genetics and molecular biology |
|---------|---------------------------------------------|
| Specific subject area | Cancer research cell biology |
| Type of data | Raw, graph and figure |
| How data were acquired | Flow cytometry (BD LSRSFortessa) |
| Data format | Analyzed data with Flowjo software and raw data (.fcs files) |
| Parameters for data collection | Percentage of cell cycle phase distributions and cell viability of cancer cells treated with LTX-315 in counterpart with non-treated cells and non-tumoral cells. |
| Description of data collection | Flow cytometry analyses were performed to quantified DNA content and propidium iodide uptake, in order to determine cell cycle progression and membrane permeability. |
| Data source location | Medellin, Colombia |
| Data accessibility | The raw data files are provided in the data in brief dataverse https://doi.org/10.7910/DVN/LO4URR and https://doi.org/10.7910/DVN/ILRIKU All other data is with this article |

### Value of the data

- The data provide the first experimental evidence about the effect of the anticancer peptide LTX-315 on the distribution of cell cycle phases in normal and skin cancer cells.
- Dataset allows comparison between LTX-315 concentrations and cell cycle distributions in two different skin cancer cell lines and in non-tumoral cells.
- The data provide valuable information on the relationships between cell cycle distribution and cell viability in non-tumoral and skin cancer-derived cells in response to LTX-315 treatment.
- Researchers can use the data as additional evidence to investigate the selectivity of the treatment with LTX-315.

### 2. Data

Histograms (Fig. 1) and bar graphs (Fig. 2) showed that treatment with peptide LTX-315, compared to non-treated cells, induced a sub-G1 peak in non-tumoral cells; this is a dose-dependent effect, the data are statistically different at 75 µM. The distinct sub-G1 peak might represent condensed or fragmented DNA, which was stained with low level DNA fluorescence and further suggests an apoptotic death [5,6]. These data are in marked contrast to the effect of the peptide observed in melanoma and epidermoid carcinoma cells, in which no sub-G1 peak is evident. The analyses of the viability data after performing PI uptake assays (Fig. 3) showed that HaCaT cells were more sensitive to LTX-315 treatment than the cancer cells.
Fig. 1. Cell cycle distribution in non-tumoral and cancer cells after LTX-315 treatment. Cells were treated with different concentrations of LTX-315 for 24 h. A. HaCaT, normal human keratinocyte cell line. B. A431, epidermoid carcinoma cells C. A375, melanoma cancer cells. The histograms show a representative example of the distribution of cell cycle phases in each treatment.
Fig. 1. Continued

Fig. 2. Quantification of cell cycle distribution of the total cell population in the different phases of the cell cycle. A. HaCaT, normal human keratinocyte cell line. B. A431, epidermoid carcinoma cells. C. A375, melanoma cancer cells. Values are expressed as mean ± SEM of three independent experiments. Two-way ANOVA for sub-G1, G1, S and G2/M populations, difference with respect to NT, * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001.

3. Experimental design, materials, and methods

3.1. LTX

LTX-315 (K–K–W–W–K–K–W–Dip–K–NH₂, Lot.91799130007/PE4961) was synthesized by the solid-phase method according to the sequence published by Camilio et al. [4] and purchased from GenScript (Piscataway Township, NJ, USA). The purity of the peptide was determined by analytical HPLC to be higher than 95%, and the molecular weight was confirmed with MALDI-TOF mass spectrometry.
3.2. Cell culture

Human skin cancer cell lines, A375 and A431, were purchased from American Type Cell Culture (ATCC). The human keratinocyte line HaCaT was employed as normal cell control. Cells were cultured at a final concentration of $2.5 \times 10^5$ cells/ml in Dulbecco’s modified Eagle’s medium (DMEM, Gibco). The medium was complemented with 5% fetal bovine serum (FCS, Gibco) and 1% penicillin/streptomycin (Gibco). Cell cultures were incubated at 37°C with 5% CO$_2$.

3.3. Treatment outline

Cells were disaggregated using trypsin-EDTA. Cell suspensions were centrifuged at 3500 rpm for 5 min, the supernatant was discarded and cell pellets were plated in 6-well plates at a final concentration of $2.5 \times 10^5$ cells/ml. After adhesion, cells were treated with different concentrations of LTX-315 (25–75 μM) for 24 h and were then processed for cell cycle and cell viability. Peptide concentrations were selected based on previous studies of LTX-315 on different tumoral cell lines [3,7–10]. In these studies, concentrations ranging from 8 to 400 μM were evaluated. However, a maximum concentration of 75 μM was considered appropriate to induce changes in the cell cycle.

3.4. Cell cycle analyses

Measuring the DNA content of cells is a well-established method to monitor cell cycle [11]. In order to analyze cell progression through the cycle, exponentially growing cells were exposed to 25, 50 or 75 μM of LTX-315 for 24 h, washed with PBS, and then disaggregated using trypsin-EDTA. One million cells per milliliter were suspended in ice-cold 70% ethanol and fixed for 1 h at 4°C. Next, cell suspensions were washed in PBS, treated with 100 μg/ml RNase, and incubated with 100 μg/ml propidium iodide (PI) for 30 min. PI fluorescence of 10,000 events was analyzed using a BD LSRFortessa flow cytometer. Percentages of cells in each phase were calculated using FlowJo. Each experiment was performed three times.
3.5. PI staining (cell viability analysis)

One of the best markers for cell death is membrane integrity. In flow cytometry, plasma membrane permeability is assessed using propidium iodide, a dye that is not permeant to live cells [12]. To assess cell viability after 24 h of 25, 50 or 75 µM LTX-315 treatments, cells were washed with PBS and disaggregated using trypsin-EDTA. Cell pellets were resuspended, stained with 1 mg/ml PI, and incubated in the dark at room temperature for 20 min. Following this, 10,000 events were analyzed by flow cytometry in BD LSRFortessa. Fluorescence was quantified using FlowJo. Each experiment was performed three times.

3.6. Statistical analysis

Data were expressed as mean ± standard error of the mean. ANOVA analyses were performed using via GraphPad Prism, with post-hoc comparisons carried out by Fisher’s protected least significant difference (FPLSD) tests. p < 0.05 was considered statistically significant.

Acknowledgments

This work was supported by the COLCIENCIAS Research Grant (111574455015, 716-2016) and Colciencias Postdoctoral Scholarship (237-2018).

Conflict of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Transparency document

Transparency data associated with this article can be found in the online version at https://doi.org/10.7910/DVN/LO4URR and https://doi.org/10.7910/DVN/ILRIKU.

Supplementary material

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.dib.2020.105443.

References

[1] R. Gordon, Skin cancer: an overview of epidemiology and risk factors, Semin. Oncol. Nurs. 29 (2013) 160–169.
[2] Z. Apalla, A. Lallias, E. Sotiriou, E. Lazaridou, D. Ioannides, Epidemiological trends in skin cancer, Dermatol Pract Concept 7 (2017) 1.
[3] K.A. Camilio, G. Berge, C.S. Ravuri, Ø. Rekdal, B. Sveinbjörnsson, Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315, Cancer Immunol. Immunother. 63 (2014) 601–613.
[4] K.A. Camilio, Ø. Rekdal, B. Sveinbjörnsson, LTX-315 (Oncopore™) a short synthetic anticancer peptide and novel immunotherapeutic agent, Oncoimmunology 3 (2014) 7–9.
[5] M. Kajstura, H.D. Halicka, J. Pryjma, Z. Darzynkiewicz, Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete “sub-G1” peaks on DNA content histograms, Cytom. Part A 71 (2007) 125–131.
[6] G. Zhong, C. Yang, S. Liu, Y. Zheng, W. Lou, J.Y. Teo, C. Bao, W. Cheng, J.P. Tan, S. Gao, Polymers with distinctive anticancer mechanism that kills MDR cancer cells and inhibits tumor metastasis, Biomaterials 199 (2019) 76–87.
S. Forveille, H. Zhou, A. Sauvat, L. Bezu, K. Müller, P. Liu, L. Zitvogel, G. Pierron, Ø. Rekdal, O. Kepp, The oncolytic peptide LTX-315 triggers necrotic cell death, Cell Cycle 14 (2015) 3506–3512.

B.E. Haug, K.A. Camilio, L.T. Eliassen, W. Stensen, J.S. Svendsen, K. Berg, B. Mortensen, G. Serin, J.-F. Mirjolet, F. Bichat, Discovery of a 9-mer Cationic Peptide (LTX-315) As a Potential First in Class Oncolytic Peptide, ACS Publications, 2016.

J. Nestvold, M.-Y. Wang, K.A. Camilio, S. Zinöcker, T.E. Tjelle, A. Lindberg, B.E. Haug, G. Kvalheim, B. Sveinbjørnsson, Ø. Rekdal, Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model, Oncoimmunology 6 (2017) e1338236.

H. Zhou, S. Forveille, A. Sauvat, V. Sica, V. Izzo, S. Durand, K. Müller, P. Liu, L. Zitvogel, Ø. Rekdal, The oncolytic peptide LTX-315 kills cancer cells through bax/bak-regulated mitochondrial membrane permeabilization, Oncotarget 6 (2015) 26599.

B.S. Cummings, R.G. Schnellmann, Measurement of cell death in mammalian cells, Curr. protoc. pharmacol. 25 (2004) 12.18. 11-12.18. 22.

P. Pozarowski, Z. Darzynkiewicz, Analysis of cell cycle by flow cytometry, Checkpoint Controls and Cancer, Springer, 2004, pp. 301–311.